Structural-functional analysis of 2,1,3-benzoxadiazoles and their N-oxides as HIV-1 integrase inhibitors

Acta Naturae

Volumn 5, Issue 16, 2013, Pages 63-72

  Korolev, S P ^a   Kondrashina, O V ^a   Druzhilovsky, D S ^b   Starosotnikov, A M ^c   Dutov, M D ^c   Bastrakov, M A ^c   Dalinger, I L ^c   Filimonov, D A ^b   Shevelev, S A ^c   Poroikov, V V ^b   Agapkina, Y Y ^a   Gottikh, M B ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

HIV 1 integrase; Inhibition; Nitrobenzofurazan; Nitrobenzofuroxan; PASS; QikProp

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84883772139     PISSN: 20758251     EISSN: None     Source Type: Journal    
DOI: 10.32607/20758251-2013-5-1-63-72     Document Type: Review

References (38)

1. Cara A., Guarnaccia F., Reitz M.S. Jr., Gallo R.C., Lori F. Virology. 1995. V. 208. P. 242-248.
2. Marcelin A.G., Ceccherini-Silberstein F., Perno C.F., Calvez V. Curr. Opin. HIV AIDS. 2009. V. 4. P. 531-537.
3. FDA approves raltegravir tablets. AIDS Patient Care STDS. 2007. V. 21. No. 11. P. 889.
4. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., et al. N. Engl. J. Med. 2008. V. 359. No. 4. P. 355-365.
5. Korolev S.P., Agapkina Y.Y., Gottikh M.B. Acta Naturae. 2011. V. 3. No. 3. P. 12-28.
6. Kobayashi M., Nakahara K., Seki T., Miki S., Kawauchi S., Suyama A., Wakasa-Morimoto C., Kodama M., Endoh T., Oosugi E., et al. Antiviral Res. 2008. V. 80. No. 2. P. 213-222.
7. Keseru G.M., Makara G.M. Nature Reviews Drug Discovery. 2009. V. 8. P. 203-212.
8. Johnson B.C., Metifiot M., Pommier Y., Highes S.H. Antimicrob. Agents Chemother. 2012. V. 56. P. 411-419.
9. Ma K., Wang P., Fu W., Wan X., Zhou L., Chu Y., Ye D. Bioorg. Med. Chem. Lett. 2011. V. 21. No. 22. P. 6724-6727.
10. Ko G.M., Reddy A.S., Garg R., Kumar S., Hadaegh A.R. Curr. Comput. Aided Drug Des. 2012. V. 8. No. 4. P. 255-270.
11. Filimonov D.A., Poroikov V.V. Probabilistic approach in activity prediction. In: Chemoinformatics Approaches to Virtual Screening. Eds. Alexandre Varnek and Alexander Tropsha. Cambridge (UK): RSC Publishing. 2008. P. 182-216.
12. Filimonov D.A., Poroikov V.V. Rus. Khim. Zhurn. 2006. V. 50. No. 2. P. 66-75.
13. Akimov D.V., Filimonov D.A., Prikazchikova T.A., Gottikh M.B., Poroikov V.V. Biomed. Khim. 2005. V. 51. No. 3. P. 335-340.
14. Druzhilovsky D.S., Filimonov D.A., Liao C., Peach M., Nicklaus M., Poroikov V.V. Biochemistry (Moscow) Supplemental Series B. Biomedical Chemistry. 2010. V. 4. No.1. P. 59-67.
15. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., et al. J. Med. Chem. 2008. V. 51. No. 18. P. 5843-5855.
16. http:www.schrodinger.com/products/14/17/
17. Handzlik J., Bajda M., Zygmunt M., Macia{ogonek}g D., Dybała M., Bednarski M., Filipek B., Malawska B., Kieć-Kononowicz K. Bioorg. Med. Chem. 2012. V. 20. No. 7. P. 2290-2303.
18. Shukla S., Kumar P., Das N., Moorthy N.S., Shrivastava S.K., Trivedi P., Srivastava R.S. Med Chem. 2012. V. 8. No. 5. 834-845.
19. Ghose A.K., Herbertz T., Hudkins R.L., Dorsey B.D., Mallamo J.P. ACS Chem. Neurosci. 2012. V. 3. No. 1. 50-68.
20. Ghosh P.B., Whitehouse M.W. J. Med. Chem. 1968. V. 11. P. 305-311.
21. Ghosh P.B. J. Chem. Soc. B. 1968. P. 334-338.
22. Terrier F., Croisat D., Chatrousse A.-P., Pouet M.-J., Halle J.-C., Jacob G. J. Org. Chem. 1992. V. 57. P. 3684-3689.
23. Zatsepin T.S., Kachlova A.V., Romanova E.A., Stetsenko D.A., Gait M.J., Oretskaya T.S. Russian J. Bioorg. Chem. 2001. V. 27. No.1. P. 39-44.
24. Leh H., Brodin P., Bischerour J., Deprez E., Tauc P., Brochon J.-C., LeCam E., Coulaud D., Auclair C., Mouscadet J.-F. Biochemistry. 2000. V. 39. P. 9285-9294.
25. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., Tchertanov L., Peytavin G., Reynes J., Mouscadet J-F., et al. Antimicrob. Agents. Chemother. 2008. V. 52. No. 4. P. 1351-1358.
26. FDA approves new 4-drug once-a-day HIV treatment AIDS Policy Law. 2012. V. 27. No. 11: 1.
27. Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.G., Subra, F., Deprez, E., Mouscadet, J.-F. Nucleic Acids Res. 2009. V. 37. P. 1193-1201.
28. Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. Proc. Natl. Acad. Sci. USA. 2010. V. 107. P. 20057-20062.
29. Quashie P.K., Sloan R.D., Wainberg M.A. BMC Med. 2012. V. 10:34
30. Puras Lutzke R.A., Vink C., Plasterk R.H. Nucleic Acids Res. 1994. V. 22. No. 20. P. 4125-4131.
31. Smolov M., Gottikh M., Tashlitskii V., Korolev S., Demidyuk I., Brochon J-C., Mouscadet J.-F., Deprez E. FEBS J. 2006. V. 273. P. 1137-1151.
32. Michel F., Crucifix C., Granger F., Eiler S., Mouscadet J.-F., Korolev S., Agapkina J., Ziganshin R., Gottikh M., Nazabal A., et al. EMBO J. 2009. V. 28. P. 980-991.
33. Krishnan L., Li X., Naraharisetty H.L., Hare S., Cherepanov P., Engelman A. Proc. Natl. Acad. Sci. U S A. 2010. V. 107. No. 36. P. 15910-15915.
34. Johnson A.A., Marchand C., Patil S.S., Costi R., Di Santo R., Burke T.R.-Jr., Pommier Y. Mol. Pharmacol. 2007. V. 71. No. 3. P. 893-901.
35. Korolev S.P., Tashlitskii V.N., Smolov M.A., Gromyko A.V., Zhuze A.L., Agapkina Yu.Yu., Gottikh M.B. HIV-1 integrase inhibition by dimeric bisbenzimidazoles with different spacers. Russian J. Mol. Biol. 2010. V. 44. No.4. P. 718-727.
36. Neamati N., Lin Z., Karki R.G., Orr A., Cowansage K., Strumberg D., Pais G.C., Voigt J.H., Nicklaus M.C., Winslow H.E., et al. J. Med. Chem. 2002. V. 45. No.. 26. P. 5661-5670.
37. http:www.merck.com/product/usa/pi_circulars/i/isentress/ isentress_pi.pdf
38. http:www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Scientific_Discussion/human/000860/WC500037408.pdf